CENTENE CORP
No SEC Form 4 filings for $CNC in the last 30 days.
UBS analyst A.J. Rice has maintained a Neutral rating on Centene (CNC) and raised its price target from $55.00 to $61.00, indicating a positive outlook for the stock. GuruFocus calculates Centene's GF Value™ at $84.03, suggesting the stock is undervalued by 30.3%. The company holds a GF Score™ of 67/100, reflecting strong profitability and financial stability despite challenges in rapid revenue growth.
Bank of America has raised its price target for Centene (US15133V1035) from $60 to $72, maintaining a Buy rating due to an improved outlook for the managed-care sector. The upgrade reflects optimism about Centene's earnings potential, particularly in US public health programs, and anticipated normalization of Medicaid margins. The company, which specializes in government-sponsored health insurance like Medicaid and Medicare Advantage, remains a key focus for US investors despite ongoing policy and execution risks.
Glenview Capital has rebalanced its investment in CVS Health, selling 3.75 million shares after an 80% total return since May 2024. Despite this reduction for diversification, CVS remains one of Glenview's top three holdings, and the firm expresses strong confidence in its near, medium, and long-term outlook. The rebalancing followed healthy Q1 results and increased annual guidance for CVS.
